To Study the Effect of Raktamrut Vati in Hemophilia

To Evaluate Safety and Efficacy of Raktamrut Vati in Hemophilia (Hereditary deficiency of other clotting factors) - NIL

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/084462

Enrollment

Registered

2025-04-09

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D682- Hereditary deficiency of other clotting factors

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosis of Hemophilia:- Participants must have a confirmed diagnosis of hemophilia. 2. Severity level (mild, moderate, severe) 3. Age Range: 4 to 60 year

Exclusion criteria

Exclusion criteria: 1. Other Bleeding Disorders: - Exclude individuals with bleeding disorders other than haemophilia. 2. Severe Co-morbid Conditions: - Exclude participants with severe cardiovascular, renal, or neuro disease, unless these are specifically being studied. 3. Recent Participation in Other Clinical Trials: -Participants who have taken part in another clinical trial within a certain period (e.g., the last 30 days) may be excluded (e.g pt with prophylaxis treatment). 4. Allergies to Study Medications: - Exclude individuals with known allergies to the medications or interventions being tested.

Design outcomes

Primary

Measure	Time frame
1. Annualized bleeding rates 2. Improvement in Clotting Time 3. Reduction in Bleeding Episodes Measure: Number of bleeding episodes per month and bleeding duration.Timepoint: 6 Weeks to 24 Weeks	—

Secondary

Measure	Time frame
Bleeding Control Reduction in Frequency Decrease in the number of bleeding episodes. Resolution Cessation of bleeding after treatment. Speed of Recovery Time taken for the bleed to stop after treatment administration. By decreasing the bleeding time of patients Hazardous complications will be decreased by reducing bleeding time & living a better life. Joint Health Improvement Pain Reduction Decreased pain in previously affected joints. Reduced Swelling Less swelling & inflammation in joints. Improved Range of Motion Better joint mobility & decreased stiffness. Absence of New Hemarthrosis No new bleeding in joints. General Well being Increased Energy Levels Reduction in fatigue & improved overall strength. Better Physical Activity Tolerance Ability to engage in daily activities with less limitation. Quality of LifeTimepoint: 6 Weeks to 3 Years	—

Measure

Time frame

Bleeding Control Reduction in Frequency Decrease in the number of bleeding episodes. Resolution Cessation of bleeding after treatment. Speed of Recovery Time taken for the bleed to stop after treatment administration. By decreasing the bleeding time of patients Hazardous complications will be decreased by reducing bleeding time & living a better life. Joint Health Improvement Pain Reduction Decreased pain in previously affected joints. Reduced Swelling Less swelling & inflammation in joints. Improved Range of Motion Better joint mobility & decreased stiffness. Absence of New Hemarthrosis No new bleeding in joints. General Well being Increased Energy Levels Reduction in fatigue & improved overall strength. Better Physical Activity Tolerance Ability to engage in daily activities with less limitation. Quality of LifeTimepoint: 6 Weeks to 3 Years

—

Countries

India

Contacts

Public ContactDr Shubham Ramnarayan Dhoot

Department Of Forensic Medicine & Toxicology

sdhoot1008@gmail.com08975656999

Outcome results